𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Interferon alpha and ribavirin in the treatment of children with chronic hepatitis C

✍ Scribed by Magdalena Figlerowicz; Wojciech Sluzewski; Arleta Kowala-Piaskowska; Iwona Mozer-Lisewska

Publisher
Springer
Year
2004
Tongue
English
Weight
162 KB
Volume
163
Category
Article
ISSN
0340-6997

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Pleural effusion associated with pegylat
Pleural effusion associated with pegylated interferon alpha and ribavirin treatment for chronic hepatitis C
✍ Amit Arora; Leonardo Vargas; Tomasz J. Kuzniar πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 128 KB

## Abstract Lung toxicity related to interferon (IFN) alpha typically takes a form of interstitial pneumonitis, granulomatous inflammation, or organizing pneumonia. We report a case of a 52‐year‐old woman, who developed pneumonitis with exudative, lymphocytic‐predominant pleural effusion following

Therapy of hepatitis C: Alpha interferon
Therapy of hepatitis C: Alpha interferon and ribavirin
✍ O Reichard; R Schvarcz; O Weiland πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 133 KB πŸ‘ 2 views

Ribavirin is a nucleoside analogue that has been evaluated as a therapy of chronic hepatitis C alone and in combination with alpha interferon. Ribavirin is well absorbed orally and is typically given in doses of 1,000 to 1,200 mg/d. Three randomized, placebo-controlled studies comprising more than 1

Interferon alfa-2b in combination with r
Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: Efficacy, safety, and pharmacokinetics
✍ Regino P. GonzΓ‘lez-Peralta; Deirdre A. Kelly; Barbara Haber; Jean Molleston; Kar πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 215 KB πŸ‘ 3 views

Chronic hepatitis C virus (HCV) infection is usually asymptomatic in children, but significant liver disease may occur. We evaluated the efficacy, safety, and pharmacokinetics of interferon alfa-2b and ribavirin in children with chronic HCV. We determined the optimal ribavirin dose in an initial coh

Merimepodib, pegylated interferon, and r
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders
✍ Vinod K. Rustgi; William M. Lee; Eric Lawitz; Stuart C. Gordon; Nezam Afdhal; Fr πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 240 KB πŸ‘ 1 views

on behalf of the MErimepodib TRiple cOmbination (METRO) study group Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC) when combined with pegylated interferon alfa 2a (Peg-IFN-a